AN OBSERVATIONAL STUDY EVALUATING TREATMENT SITUATION OF ADJUVANT NIVOLUMAB FOR MUSCLE-INVASIVE UROTHELIAL CARCINOMA IN JAPAN - ANNIVERSARY

AKANO TOMOYOSHI0 个研究点目标入组 400 人开始时间: 2023年5月26日最近更新: 2023年11月20日

适应症

试验速览

暂无简介。

•1) Patients aged 18 years or older
•2) Patients with histologically definitive diagnosis of MIUC at each study site and who received nivolumab after radical resection
•3) Patients who present at least once to the study site after nivolumab treatment or who have survival data
•4) In the case of a patient who is currently visiting a study site participating in the study, the patient must be fully informed of their enrollment in the study and provide written consent of his/her own free will after sufficient understanding.

•Patients who did not meet any of the following criteria at the time of obtaining consent will not be included in this study.
•1) Patients who underwent only partial resection for MIUC
•2) Patients treated with chemotherapy, radiotherapy, biologics (anticancer agents), intravesical chemotherapy, or BCG therapy from the time of radical resection of MIUC to the start of nivolumab
•3) Those who received investigational drugs after being diagnosed with MIUC and before or administered nivolumab
•4) Patients previously treated with immune checkpoint inhibitors prior to nivolumab treatment
•5) Patients judged to be inappropriate for enrollment in this study by the investigator at each participating study site

发起方

AKANO TOMOYOSHI